A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn's disease.

6Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Crohn's disease is characterized by chronic transmural inflammation of the bowel and is associated with serious complications, such as bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor surgical therapy provides a cure for Crohn's disease, the primary goals of therapy are to induce and maintain remission and prevent complications. As a biologic agent, infliximab, a monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease that does not respond to other medical therapies or surgery. Infliximab has proven to be very effective for inducing and maintaining remission in Crohn's disease; however, infliximab treatment has several potential complications. Here, we report a case of free perforation following a therapeutic response after an initial dose of infliximab for Crohn's disease. This is the first case report describing a free perforation in a Crohn's disease patient after an initial dose of infliximab.

Cite

CITATION STYLE

APA

Lim, C. S., Moon, W., Park, S. J., Park, M. I., Kim, H. H., Kim, J. B., … Lee, S. H. (2013). A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn’s disease. The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi. https://doi.org/10.4166/kjg.2013.62.3.169

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free